Praxis Precision Medicines revenue was $8.55M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $7.5M, up 2,371.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PRAX annual revenue was $8.6M, with 249.5% growth year-over-year.
PRAX past revenue growth
How has PRAX's revenue growth performed historically?
On Invalid Date, Praxis Precision Medicines (NASDAQ: PRAX) reported Q4 2024 revenue of $7.46 million up 1,349.13% year over year. In the same quarter last year, Praxis Precision Medicines's revenue was $515.00 thousand.
What was Praxis Precision Medicines's revenue in 2024?
Praxis Precision Medicines's annual revenue for the twelve months ending Dec 31, 2024 was $8.55 million, a 249.53% increase year over year.
How much does Praxis Precision Medicines make in a day?
Based on Praxis Precision Medicines annual revenue for the past five years, PRAX makes an average of $6,027.40 per day.
What was Praxis Precision Medicines's annual revenue growth in the past year?
As of Q2 2025, Praxis Precision Medicines's revenue has grown 249.53% year over year. This is 187.78 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Praxis Precision Medicines's revenue in the past year totaled $8.55 million.
How much does Praxis Precision Medicines make in a year?
Praxis Precision Medicines's revenue by year for the past five years is:
Praxis Precision Medicines's revenue for the twelve months ending Dec 31, 2024 was $8.55 million, a 249.53% increase year over year.
Praxis Precision Medicines's annual revenue for Dec 31, 2023 was $2.45 million, a Infinity% increase from 2022.
Praxis Precision Medicines's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
Praxis Precision Medicines's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
Praxis Precision Medicines's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.